Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Tongue Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Parathyroid Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non-Small-Cell Lung 1NSCLC 1Gastrointestinal Neoplasms 1Esthesioneuroblastoma, Olfactory 1EGFR Mutation Positive Non-small Cell Lung Cancer 1Carcinoma, Medullary 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Adenocarcinoma, Follicular 1Adenocarcinoma of Lung 1

Interventions

Standard of Care 1Parathyroidectomy 1Gefitinib 1Control Groups 1Congresses as Topic 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Parathyroid Neoplasms × Gefitinib × Clear all
NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Completed
40 enrolled
CNSEndocrineHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Parathyroid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡